ReviewClinical & developmental immunology2013
Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.
Review in Clinical & developmental immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments.Frontiers in immunology · 2022Pooled it
- Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Characteristics of mismatched eplets affecting de novo donor-specific antibody production and antibody-mediated rejection after kidney transplantation.BMC nephrology · 2025Article
- Non-Invasive Biomarkers for Early Diagnosis of Kidney Allograft Dysfunction: Current and Future Applications in the Era of Precision Medicine.Medicina (Kaunas, Lithuania) · 2025Review
- Variations in de novo donor-specific antibody development among HLA-DQ mismatches in kidney transplant recipients.PloS one · 2025Article
- Assessment of Donor Derived Cell Free DNA (dd-cfDNA) at Surveillance and at Clinical Suspicion of Acute Rejection in Renal Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Continuation of immunosuppression vs. immunosuppression weaning in potential repeat kidney transplant candidates: a care management perspective.Frontiers in nephrology · 2023Review
- Utilization of HCV viremic donors in kidney transplantation: a chance or a threat?Renal failure · 2022Review
- Incidence of acute rejection and patient survival in combined heart-liver transplantation.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2022Article
- Induction therapy with thymoglobulin or interleukin-2 receptor antagonist for Chinese recipients of living donor renal transplantation: a retrospective study.BMC nephrology · 2019Article
- Age-associated decrease in de novo donor-specific antibodies in renal transplant recipients reflects changing humoral immunity.Immunity & ageing : I & A · 2019Article
- Psychosocial Assessment of Candidates for Transplantation (PACT) Score Identifies High Risk Patients in Pediatric Renal Transplantation.Frontiers in pediatrics · 2019Article
- Prevalence and Clinical Impact of Donor-Specific Alloantibody Among Intestinal Transplant Recipients.Transplantation · 2017Article
- Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection.Journal of immunology research · 2017Review
- The Role of Humoral Alloreactivity in Liver Transplantation: Lessons Learned and New Perspectives.Journal of immunology research · 2017Review
- Novel Non-Histocompatibility Antigen Mismatched Variants Improve the Ability to Predict Antibody-Mediated Rejection Risk in Kidney Transplant.Frontiers in immunology · 2017Article
- Advances in diagnostics for transplant rejection.Expert review of molecular diagnostics · 2016Review
- Some considerations on the current debate about typing resolution in solid organ transplantation.Transplantation research · 2016Article
- Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression.Transplant international : official journal of the European Society for Organ Transplantation · 2015Review
- Role ofAsian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney transplantation has evolved over more than half a century and remarkable progress has been made in patient and graft outcomes. Despite these advances, chronic allograft dysfunction remains a major problem. Among other reasons, de novo formation of antibodies against donor human leukocyte antigens has been recognized as one of the major risk factors for reduced allograft survival. The type of treatment in the presence of donor specific antibodies (DSA) posttransplantation is largely related to the clinical syndrome the patient presents with at the time of detection. There is no consensus regarding the treatment of stable renal transplant recipients with circulating de novo DSA. On the contrast, in acute or chronic allograft dysfunction transplant centers use various protocols in order to reduce the amount of circulating DSA and achieve long-term graft survival. These protocols include removal of the antibodies by plasmapheresis, intravenous administration of immunoglobulin, or depletion of B cells with anti-CD20 monoclonal antibodies along with tacrolimus and mycophenolate mofetil. This review aims at the comprehension of the clinical correlations of de novo DSA in kidney transplant recipients, assessment of their prognostic value, and providing insights into the management of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.